Semmelweis Publications
  • Main page

    • Pásztor-Csizmarik, Anita Semmelweis University affiliated publications (2021-2026)

    Year:
    Order by:
    Authorship:
    Number of publications: 24
    1.
    Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer
    Szarvas, T;Csizmarik, A;Fazekas, T;Hüttl, A;Nyirády, P;Hadaschik, B;Grünwald, V;Püllen, L;Jurányi, Z;Kocsis, Z;Shariat, SF;Sevcenco, S;Maj-Hes, A;Kramer, G
    D1
    BJU INTERNATIONAL
    2021.
    DOI:10.1111/bju.15086 (Copy DOI)
    2.
    Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis
    Fazekas, T;Széles, AD;Teutsch, B;Csizmarik, A;Vékony, B;Kói, T;Acs, N;Hegyi, P;Hadaschik, B;Nyirády, P;Szarvas, T
    D1
    EUROPEAN UROLOGY ONCOLOGY
    2024.
    DOI:10.1016/j.euo.2023.09.001 (Copy DOI)
    3.
    Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma
    Váradi, M;Horváth, O;Soos, E;Csizmarik, A;Németh, B;Gyorffy, B;Kenessey, I;Reis, H;Koll, F;Oláh, C;Hadaschik, B;Krafft, U;Grünwald, V;Mairinger, F;Wessolly, M;Hoffmann, MJ;Grunewald, CM;Niegisch, G;Cotarelo, CL;Maráz, A;Kuthi, L;Szász, AM;Herold, Z;Posta, M;Bátai, B;Nyirády, P;Szarvas, T
    D1
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    2025.
    DOI:10.1007/s00262-025-04224-8 (Copy DOI)
    4.
    Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas
    Varadi, M;Nagy, N;Reis, H;Hadaschik, B;Niedworok, C;Modos, O;Szendroi, A;Ablat, J;Black, PC;Keresztes, D;Csizmarik, A;Olah, C;Gaisa, NT;Kiss, A;Timar, J;Toth, E;Csernak, E;Gerstner, A;Mittal, V;Karkampouna, S;de Julio, MK;Gyorffy, B;Bedics, G;Rink, M;Fisch, M;Nyirady, P;Szarvas, T
    Q1
    CANCER MEDICINE
    2023.
    DOI:10.1002/cam4.5639 (Copy DOI)
    5.
    High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
    Krafft, U;Olah, C;Reis, H;Kesch, C;Darr, C;Grunwald, V;Tschirdewahn, S;Hadaschik, B;Horvath, O;Kenessey, I;Nyirady, P;Varadi, M;Modos, O;Csizmarik, A;Szarvas, T
    Q1
    CANCERS
    2021.
    DOI:10.3390/cancers13112548 (Copy DOI)
    6.
    Elevated Levels of Serum Thymidine Kinase 1 Predict Poor Survival for Patients with Metastatic Prostate Cancer
    Murtola, T.J.; Siltari, A.; Raittinen, P.; Tammela, T.L.J.; Linder, S.; Csizmarik, A.; Kramer, G.; Szarvas, T.;
    D1
    EUROPEAN UROLOGY OPEN SCIENCE 2666-1691 2666-1683
    2024.
    DOI:10.1016/j.euros.2024.10.010 (Copy DOI)
    Semmelweis University authors: Pásztor-Csizmarik, Anita, Szarvas, Tibor,
    Semmelweis University departments: Semmelweis University, Faculty of Medicine, Department of Urology,
    7.
    Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
    Széles, A;Fazekas, T;Váncsa, S;Váradi, M;Kovács, PT;Krafft, U;Grünwald, V;Hadaschik, B;Csizmarik, A;Hegyi, P;Váradi, A;Nyirády, P;Szarvas, T
    D1
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    2023.
    DOI:10.1007/s00262-022-03328-9 (Copy DOI)
    8.
    Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer
    Csizmarik, A;Hadaschik, B;Kramer, G;Nyirady, P;Szarvas, T
    Q1
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
    2021.
    DOI:10.1016/j.urolonc.2021.01.030 (Copy DOI)
    9.
    MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients
    Szarvas, T;Hoffmann, MJ;Olah, C;Szekely, E;Kiss, A;Hess, J;Tschirdewahn, S;Hadaschik, B;Grotheer, V;Nyirady, P;Csizmarik, A;Varadi, M;Reis, H
    Q2
    DIAGNOSTICS
    2021.
    DOI:10.3390/diagnostics11010048 (Copy DOI)
    10.
    The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy
    Szarvas, T;Csizmarik, A;Váradi, M;Fazekas, T;Hüttl, A;Nyirády, P;Hadaschik, B;Grünwald,;Tschirdewahn, S;Shariat, SF;Sevcenco, S;Maj-Hes, A;Kramer, G
    Q1
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
    2021.
    DOI:10.1016/j.urolonc.2020.09.005 (Copy DOI)
    11.
    Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in Urothelial Bladder Cancer
    Juhász, D;Csizmarik, A;Váradi, M;Bacso, D;Kubik, A;Szucs, M;Székely, E;Al-Nader, M;Mahmoud, O;Krafft, U;Hadaschik, B;Nyirády, P;Szarvas, T
    Q1
    CLINICAL GENITOURINARY CANCER
    2025.
    DOI:10.1016/j.clgc.2025.102421 (Copy DOI)
    12.
    Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma
    Kovács, PT;Mayer, T;Csizmarik, A;Váradi, M;Oláh, C;Széles, A;Tschirdewahn, S;Krafft, U;Hadaschik, B;Nyirády, P;Riesz, P;Szarvas, T
    Q1
    BIOMEDICINES
    2022.
    DOI:10.3390/biomedicines10030698 (Copy DOI)
    13.
    Precision Oncology Approach for Urachal Carcinoma: A Clinical Case Report
    Juhász, D;Csizmarik, A;Szalontai, J;Keszthelyi, A;Dér, B;Kubik, A;Szucs, M;Kenessey, I;Ertl, IE;Berger, W;Englinger, B;Shariat, SF;Nyirády, P;Szarvas, T
    D1
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
    2024.
    DOI:10.3390/ijms252413315 (Copy DOI)
    14.
    Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis
    Fazekas, T;Széles, AD;Teutsch, B;Csizmarik, A;Vékony, B;Váradi, A;Kói, T;Lang, Z;Acs, N;Kopa, Z;Hegyi, P;Hadaschik, B;Grünwald, V;Nyirády, P;Szarvas, T
    D1
    PROSTATE CANCER AND PROSTATIC DISEASES
    2023.
    DOI:10.1038/s41391-022-00626-2 (Copy DOI)
    15.
    Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer
    Keresztes, D;Csizmarik, A;Nagy, N;Módos, O;Fazekas, T;Bracht, T;Sitek, B;Witzke, K;Puhr, M;Sevcenco, S;Kramer, G;Shariat, S;Küronya, Z;Takács, L;Tornyi, I;Lázár, J;Hadaschik, B;Lászik, A;Szucs, M;Nyirády, P;Szarvas, T
    Q2
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
    2022.
    DOI:10.1111/jcmm.17141 (Copy DOI)
    16.
    Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer
    Csizmarik, A;Nagy, N;Keresztes, D;Váradi, M;Bracht, T;Sitek, B;Witzke, K;Puhr, M;Tornyi, I;Lázár, J;Takács, L;Kramer, G;Sevcenco, S;Maj-Hes, A;Hadaschik, B;Nyirády, P;Szarvas, T
    D1
    PROSTATE CANCER AND PROSTATIC DISEASES
    2024.
    DOI:10.1038/s41391-023-00713-y (Copy DOI)
    17.
    High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
    Széles, A;Kovács, PT;Csizmarik, A;Váradi, M;Riesz, P;Fazekas, T;Váncsa, S;Hegyi, P;Oláh, C;Tschirdewahn, S;Darr, C;Krafft, U;Grünwald, V;Hadaschik, B;Horváth, O;Nyirády, P;Szarvas, T
    Q1
    BIOMEDICINES
    2022.
    DOI:10.3390/biomedicines10102560 (Copy DOI)
    18.
    Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer
    Csizmarik, A;Keresztes, D;Nagy, N;Bracht, T;Sitek, B;Witzke, K;Puhr, M;Tornyi, I;Lázár, J;Takács, L;Kramer, G;Sevcenco, S;Maj-Hes, A;Jurányi, Z;Hadaschik, B;Nyirády, P;Szarvas, T
    Q1
    INTERNATIONAL JOURNAL OF CANCER
    2022.
    DOI:10.1002/ijc.34159 (Copy DOI)
    19.
    Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and Meta-Analysis
    Kubik, A;das Virgens, IPA;Szabó, A;Váradi, M;Csizmarik, A;Keszthelyi, A;Majoros, A;Fehérvári, P;Hegyi, P;Acs, N;Nyirády, P;Szarvas, T
    D1
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
    2023.
    DOI:10.3390/ijms24097859 (Copy DOI)
    20.
    A karboplatin-kemoterapia hatekonysaga egy attetes, kasztraciorezisztens, prosztatarakos betegben
    Nagy, ND;Fazekas, T;Baghy, K;Papp, G;Csizmarik, A;Szucs, M;Nyirady, P;Szarvas, T
    Q4
    ORVOSI HETILAP
    2021.
    DOI:10.1556/650.2021.32112 (Copy DOI)
    21.
    A prosztatarák genetikai hátterének aktuális terápiás és familiáris vonatkozásai
    Dér, Bálint; Fazekas, Tamás; Csizmarik, Anita; Soós, Áron; Fekete, Bálint; Nyirády, Péter; Szarvas, Tibor;
    Q4
    MAGYAR ONKOLÓGIA 0025-0244 2060-0399
    2023.
    22.
    A prosztatarák és húgyhólyagrák molekuláris hátterének terápiás vonatkozásai
    Szarvas, Tibor; Csizmarik, Anita; Váradi, Melinda; Oláh, Csilla; Nyirády, Péter;
    ORVOSKÉPZÉS 0030-6037
    2021.
    23.
    A prosztatarák molekuláris klasszifikációja és annak klinikai vonatkozásai
    Csizmarik, Anita; Oláh, Csilla; Soós, Áron; Nyirády, Péter; Szarvas, Tibor;
    KLINIKAI ONKOLÓGIA 2064-5058 2498-8596
    2023.
    24.
    Új utak a prosztatarák terápiájában: a genetikai mintázat szerepe a célzott kezelések kiválasztásában
    Fazekas, Tamás; Dér, Bálint; Csizmarik, Anita; Soós, Áron; Fekete, Bálint; Nyirády, Péter; Szarvas, Tibor;
    MAGYAR UROLÓGIA 0864-8921
    2023.
    DOI:10.22591/magyurol.2023.2.fazekast.75 (Copy DOI)

    Navigation

    Main page

    Publication search

    Department ranking

    Author ranking

    Author search

    Articles recently published in SJR D1 journals

    Top papers of the university

    Top field weighted citation impact publications

    Highly Cited Articles of Semmelweis University

    Semmelweis Publications
    Release: 2026_7
    Department data last refreshed at: 22.06.2026
    Author data last refreshed at: 22.06.2026
    (c) Semmelweis University - Central Library